Cargando…

Real-time analysis of the binding of fluorescent VEGF(165)a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes

Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis. Here we have used a novel stoichiometric protein-labeling method to generate a fluorescent variant of VEGF (VEGF(165)a-TMR) labeled on a single cysteine within each protomer of the antiparallel VEGF homodimer. VEGF(1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kilpatrick, Laura E., Friedman-Ohana, Rachel, Alcobia, Diana C., Riching, Kristin, Peach, Chloe J., Wheal, Amanda J., Briddon, Stephen J., Robers, Matthew B., Zimmerman, Kris, Machleidt, Thomas, Wood, Keith V., Woolard, Jeanette, Hill, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457915/ https://www.ncbi.nlm.nih.gov/pubmed/28392095 http://dx.doi.org/10.1016/j.bcp.2017.04.006

Ejemplares similares

Effects of receptor tyrosine kinase inhibitors on VEGF(165)a- and VEGF(165)b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
por: Carter, Joanne J, et al.
Publicado: (2015)

Real-Time Ligand Binding of Fluorescent VEGF-A Isoforms that Discriminate between VEGFR2 and NRP1 in Living Cells
por: Peach, Chloe J., et al.
Publicado: (2018)

Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
por: Peach, Chloe J., et al.
Publicado: (2018)

Complex Formation between VEGFR2 and the β(2)-Adrenoceptor
por: Kilpatrick, Laura E., et al.
Publicado: (2019)

Comparison of the ligand‐binding properties of fluorescent VEGF‐A isoforms to VEGF receptor 2 in living cells and membrane preparations using NanoBRET
por: Peach, Chloe J., et al.
Publicado: (2019)

NanoBiT Complementation to Monitor Agonist-Induced Adenosine A(1) Receptor Internalization
por: Soave, Mark, et al.
Publicado: (2019)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Inhibition of VEGF(165)/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis
por: Chen, Chi-Kuan, et al.
Publicado: (2016)

Application of BRET to monitor ligand binding to GPCRs
por: Stoddart, Leigh A, et al.
Publicado: (2015)

The splicing factor YBX1 promotes the progression of osteosarcoma by upregulating VEGF(165) and downregulating VEGF(165b)
por: Quan, Bingxuan, et al.
Publicado: (2023)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

Kinetic analysis of antagonist-occupied adenosine-A(3) receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism
por: Corriden, Ross, et al.
Publicado: (2014)

The role of VEGF-A(165)b in trophoblast survival
por: Bills, Victoria L, et al.
Publicado: (2014)

VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010)

Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (Spermophilus dauricus)
por: Yao, Yuchen, et al.
Publicado: (2021)

In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF(165) neutralization
por: Millán-Gómez, Dalia, et al.
Publicado: (2018)

A critical role for VEGF and VEGFR2 in NMDA receptor synaptic function and fear-related behavior
por: De Rossi, P, et al.
Publicado: (2016)

Fluorescence correlation spectroscopy, combined with bimolecular fluorescence complementation, reveals the effects of β-arrestin complexes and endocytic targeting on the membrane mobility of neuropeptide Y receptors
por: Kilpatrick, Laura E., et al.
Publicado: (2012)

Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis
por: Stevens, Megan, et al.
Publicado: (2019)

Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies
por: Soave, Mark, et al.
Publicado: (2020)

VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas
por: Corlan, Ana Silvia, et al.
Publicado: (2019)

Targeting Anti-Angiogenic VEGF(165)b–VEGFR1 Signaling Promotes Nitric Oxide Independent Therapeutic Angiogenesis in Preclinical Peripheral Artery Disease Models
por: Kuppuswamy, Sivaraman, et al.
Publicado: (2022)

Efficient G protein coupling is not required for agonist‐mediated internalization and membrane reorganization of the adenosine A(3) receptor
por: Stoddart, Leigh A., et al.
Publicado: (2021)

Detection of genome‐edited and endogenously expressed G protein‐coupled receptors
por: Soave, Mark, et al.
Publicado: (2021)

Urea-Peptide Hybrids as VEGF-A(165)/NRP-1 Complex Inhibitors with Improved Receptor Affinity and Biological Properties
por: Puszko, Anna K., et al.
Publicado: (2020)

Inhibition of retinal neovascularization by siRNA targeting VEGF(165)
por: Xia, Xiao-bo, et al.
Publicado: (2008)

Systems Pharmacology of VEGF165b in Peripheral Artery Disease
por: Clegg, Lindsay E., et al.
Publicado: (2017)

VEGF-VEGFR Signals in Health and Disease
por: Shibuya, Masabumi
Publicado: (2014)

Levels of vascular endothelial growth factor-A(165b) (VEGF-A(165b)) are elevated in experimental glaucoma
por: Ergorul, Ceren, et al.
Publicado: (2008)

Pharmacology under the microscope: the use of fluorescence correlation spectroscopy to determine the properties of ligand–receptor complexes
por: Briddon, Stephen J., et al.
Publicado: (2007)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
por: Dziobek, Konrad, et al.
Publicado: (2019)

Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer
por: Zajkowska, Monika, et al.
Publicado: (2018)

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
por: Lanitis, Evripidis, et al.
Publicado: (2021)

Probe dependence of allosteric enhancers on the binding affinity of adenosine A(1)‐receptor agonists at rat and human A(1)‐receptors measured using NanoBRET
por: Cooper, Samantha L., et al.
Publicado: (2019)

Probing High Affinity Sequences of DNA Aptamer against VEGF(165)
por: Kaur, Harleen, et al.
Publicado: (2012)

Designing and Development of a Tandem Bivalent Nanobody against VEGF(165)
por: Khodabakhsh, Farnaz, et al.
Publicado: (2021)

Subtype selective fluorescent ligands based on ICI 118,551 to study the human β2‐adrenoceptor in CRISPR/Cas9 genome‐edited HEK293T cells at low expression levels
por: Goulding, Joëlle, et al.
Publicado: (2021)

The role of the VEGF-C/VEGFR-3 axis in cancer progression
por: Su, J-L, et al.
Publicado: (2007)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h90b6n8tspndun8t1acj3vt20b